Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on β-receptor occupancy

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 8, 2003, Pages 358-364

  Miki, A ^a   Tanaka, Y ^b   Ohtani, H ^a   Sawada, Y ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Tanaka Clinic   (Japan)

Author keywords

Asthma; Betaxolol; Receptor occupancy; 1 selective blocking agents

Indexed keywords

ACEBUTOLOL; AMBROXOL; ANTIASTHMATIC AGENT; ATENOLOL; ATORVASTATIN; BECLOMETASONE DIPROPIONATE; BENIDIPINE; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETAXOLOL; BISOPROLOL; BROTIZOLAM; CELIPROLOL; ETHYL LOFLAZEPATE; LOSARTAN POTASSIUM; METOPROLOL TARTRATE; PRANLUKAST; PREDNISOLONE; PROPRANOLOL; SIMVASTATIN; TEPRENONE; THEOPHYLLINE;

AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CALCULATION; CARDIOSELECTIVITY; CASE REPORT; COUGHING; DETERIORATION; DISEASE SEVERITY; DRUG SELECTIVITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; MOLECULAR MODEL; PHARMACODYNAMICS; PULSE RATE; RECEPTOR OCCUPANCY; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 0042031220     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41358     Document Type: Article

References (24)

1. ADRAC 1995 Systemic adverse reaction with betaxolol eye drops. Med J Aust 162: 84
2. Ananthanarayan CR, Vaile SJ, Feldman F 1993 Acute episode of asthma following topical administration of betaxolol eye drops. Can J Ophthalmol 28: 80-81
3. Barber HE, Hawksworth GM, Kitteringham NR, Petersen J, Petrie J, Swann JW 1978 Protein binding of atenolol and propranolol to human serum albumin and in human plasma (proceedings). Br J Clin Pharmacol 6:446-447
4. Bessho H, Suzuki J, Nrimatsu A, Tobe A 1990 Cardio-selective β-adrenoceptor blocking action of betaxolol in vitro and in vivo. Oyo Yakuri Pharmacometrics 39: 521-527
5. Decalmer PBS, Chatterjee SS, Cruickshank JM, Benson MK, Sterling GM 1978 Beta-blockers and asthma. Br Heart J 40: 184-189
6. Evans GH, Nies AS, Shand DG 1973 The disposition of Propranolol III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 186: 114-122
7. Fogari R, Zoppi A, Tettamanii F, Polletti L, Rizzardi G, Fiocchi G 1990 Comparative effects of celiprolol, propranolol, oxprenolol and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 4: 1145-1150
8. Harting J, Becker KH, Bergmann R, Enenkel HJ, Fuchs A, Jonas R et al 1986 Pharmacodynamic profile of the selective β-adrenoceptor antagonist bisoprolol. Arzneimittelforschung 36: 200-208
9. Ishizaki T, Oyama Y 1983 Atenolol dose-finding studies. Drugs 25: 42-49
10. Johansson KA, Appelgren C, Borg KO, Elofsson R 1974 Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. Acta Pharm Suec 11: 333-346
11. Kunka RL, Wong YY, Andersen RL, Haack DG 1989 Steady state fluctuation and variability of betaxolol and atenolol plasma levels. Ther Drug Monit 11: 523-527
12. Miura A, Kimura Y, Inoue K, Matuzaki T, Oghi S, Hamada K et al 1990 Pharmacological studies of celiprolol I. Folia Pharmacol Japon 95: 191-200
13. Nakazima M, Kanematu M, Takiguchi Y Mizuno A 1988 Phase I study of celiprolol. J Clin Ther Med 4: 1075-1090
14. Niwa T, Nozawa M, Iida S 1990 Studies on the metabolic fate of ±-[4-[2-cyclopropylmethoxy ethyl]phenoxy]-3-isopropylamino-2-propanol hydrochloride betaxolol hydrochloride 5-protein binding in rat, dog and human. Jpn Pharmacol Ther 18 (Suppl 7): 215
15. Ohashi K, Ebihara A, Kondo K, Usami M 1984 Clinical pharmacokinetics and pharmacological action of a long-acting formulation of propranolol. Arzneimittelforschung Drug Res 36: 507-512
16. Palminteri R, Kaik G 1983 Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol. Eur J Clin Pharmacol 24: 741-745
17. Rigby JW, Scott AK, Hawksworth GM, Petrie C 1985 A comparison of the pharmacokinetics of atenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol 20: 327-331
18. Simizu H, Noguchi H, Uno K, Takashima M, Onishi A, Ueki M 1991 Multiple-dose pharmacokinetic study of slow-release metoprolol tartrate 120 mg tablet in healthy volunteers. Xenobiotics 6: 567-578
19. Takeuchi K, Kawarabayashi K, Murai K, Nishikimi T, Yasunari K, Tanizawa S et al 1985 Phase I study of bisoprolol hemifumarate TA-4708: Oral single-dose and oral 7-day-dosing study. Jpn Pharmacol Ther 13: 5761-5793
20. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I 1975 Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br HeartJ 37: 1022-1036
21. Watanabe S, Sugihara K, Morio A, Sugiyama M, Nomura A 1989 Studies on the fate of celiprolol (II) absorption, distribution, metabolism, excretion and effect on the hepatic drug-metabolizing enzyme activities in rats after repeated oral administration. Iyakuhin Kenkyu 20: 1047
22. Wellstein A, Palm D, Belz GG, Leopold G, Bhring KU, Pabst J 1986 Concentration kinetics of propranolol, bisoprolol and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. J Cardiovasc Pharmacol 8 (Suppl 11): S41-S45
23. Yamada Y, Ito K, Nakamura K, Sawada Y, Iga T 1993 Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure pharmacokinetic/pharmacodynamic relationship. Biol Pharm Bull 16: 1251-1259
24. Yamada Y, Matsuyama K, Ito K, Sawada Y, Iga T 1995 Risk assessment of adverse pulmonary effects induced by adrenaline β-receptor antagonists and rational drugs dosage regimen based on receptor occupancy. J Pharmacokinet Biopharm 23: 463-478